Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study Evaluating ET-01 in Subjects With Transfusion Dependent β-Thalassaemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Subjects and/or legal representative fully understand and voluntarily sign informed consent forms.~* Diagnosis of transfusion dependent β-thalassemia (β-TDT) as defined by protocol.~* Be not appropriate to receive conventional allogeneic hematopoietic stem cell transplantation.~* Lansky/Karnofsky score ≥ 70%.~* Eligible for hematopoietic stem cell transplantation and conditioning with busulfan as per investigator's judgement.~Other protocol defined inclusion criteria may apply.~Key Exclusion Criteria:~* Subjects with associated α-thalassemia.~* Subjects with any clinically significant acute or uncontrolled infections.~* History of uncontrolled epilepsy or other mental disorders.~* Previous treatment with allogeneic bone marrow transplantation or gene therapy.~Other protocol defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- ET-01 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).